Antiglaucoma Drugs Market - By Product Type (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication), By Disease Condition Type (Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma), By Prescription Type (OTC Drugs, Prescription Drugs), And By Region, Opportunities And Strategies – Global Antiglaucoma Drugs Market Forecast To 2030

Starting Price : $4000.00 | Pages : 290 | Published : December 2020 | | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN

Antiglaucoma Drugs Market Definition

The antiglaucoma drugs market consists of sales of antiglaucoma drugs and related services by entities (organizations, sole traders and partnerships) that produce antiglaucoma drugs to treat glaucoma conditions. Glaucoma is a group of eye conditions that lead to damage of the optic nerve of the eye causing blindness and impaired vision. Some of the major drugs include Xalantan, Lumigan, and Travatan among others.

The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing. Antiglaucoma drug manufacturers produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

Antiglaucoma Drugs Market Size

The global antiglaucoma drugs market reached a value of nearly $6,591.8 million in 2019, having increased at a compound annual growth rate (CAGR) of 4.2% since 2015. The market is expected to decline from $6,591.8 million in 2019 to $5,191.2 million in 2020 at a rate of -21.2%. The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 5.0% to $6,659.2 million in 2021 and reach $ 7,345.6 million in 2023 at a CAGR of 2.7%. The market is expected to reach $8,089.0 million in 2025 at a CAGR of 4.9% and $10,767.9 million in 2030 at a CAGR of 5.9%.

Growth in the historic period resulted from increase in research and development expenditure, aging population and increase in healthcare expenditure. Factors that negatively affected growth in the historic period were low healthcare access and awareness.

Going forward, increase in prevalence of glaucoma and increasing geriatric population will drive the growth. Factors that could hinder the growth of the antiglaucoma drugs market include high cost of drugs and costly drug approvals.

Antiglaucoma Drugs Market Drivers

The key drivers of the antiglaucoma drugs market include:

Increasing Prevalence Of Glaucoma

Increasing incidence and prevalence of glaucoma is expected to support the growth of the anti-glaucoma drugs market. Eye disorders such as glaucoma are becoming major causes of visual impairment and blindness globally. Globally, glaucoma ranks the second major cause of blindness after cataract. By 2050, an estimated 7.32 million people in the USA are expected to have primary open angle glaucoma (POAG), a rise from 3.15 million in 2015. Worldwide, the prevalence of glaucoma is increasing and is expected to affect 111.8 million people by 2040. The prevalence of open-angle glaucoma is reported to be highest in Africa and that of narrow-angle in Asia. The increasing incidence and prevalence of glaucoma is expected to drive the anti-glaucoma drugs market.

Antiglaucoma Drugs Market Restraints

The key restraints on the antiglaucoma drugs market include:

Long And Costly Drug Approvals

Strict regulations around the market launch of new drugs leading to prolonged and expensive development cycles are expected to restrain the anti-glaucoma market. A drug approval process involves a series of expensive research stages and regulatory approvals. The drug approval process includes about four phases of clinical trials and various stages of a screening process with the regulatory body such as the FDA in the USA. The costs of failed clinical trials are high as they account for investments involved in clinical trial phases. According to a report by Forbes, a pharmaceutical company spends about $350 million per drug before launching it in the market, which indicates high drug approval costs. An example of a prolonged clinical trial is a new drug for glaucoma treatment, Vyzulta, which was approved by the FDA only after its safety and effectiveness were assessed and the FDA was finally satisfied with the good manufacturing practices at Bausch + Lomb’s facility in Tampa, Florida, US, where the company is manufacturing this newly-approved drug. The process included two complete response letters from the FDA. Long and costly drug approvals of new drug candidates are expected to continue restraining the anti-glaucoma drugs market.

Antiglaucoma Drugs Market Trends

Major trends shaping the antiglaucoma drugs market include the following –

Rho-Kinase Inhibitors In Glaucoma Treatment

Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. Rho-kinase inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Ripasudil hydrochloride hydrate in the form of eye drops is approved in Japan for the treatment of glaucoma and ocular hypertension. Netarsudil formulated as an ophthalmic solution is used to treat intraocular pressure in patients with open-angle glaucoma.

Development Of Combination Therapies

Development of combination therapies for the treatment of eye related diseases including glaucoma is an emerging trend in the anti-glaucoma drugs market. Combination therapy involves the use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of eye drops or drug administration, and reduce the possibility of vascular endothelial growth factor (VEGF) expression, choroidal neovascularization and inflammation. For instance, companies such as Allergan, Akorn and Alcon provide commercially available combination drop therapies with dosing frequency of twice or thrice daily. Similarly, companies such as Ocular Science and Imprimis Pharmaceuticals offer formulations that combine two, three, or four eye drops, thus reducing the burden and load typically associated with daily use of multiple drops.

Opportunities And Recommendations In The Antiglaucoma Drugs Market

Opportunities – The top opportunities in the antiglaucoma drugs market segmented by product type will arise in the prostaglandin analog market segment, which will gain $308.8 million of global annual sales by 2023. The top opportunities in the antiglaucoma drugs market segmented by condition type will arise in the open-angle glaucoma segment, which will gain $570.2 million of global annual sales by 2023. The top opportunities in the antiglaucoma drugs market segmented by prescription type will arise in the OTC drugs market segment, which will gain $962.5 million of global annual sales by 2023.

The antiglaucoma drugs market size will gain the most in USA at $344.8 million. Market-trend-based strategies for the antiglaucoma drugs market include focus on development of rho kinase inhibitors for glaucoma treatment, development of combination therapies and investments in artificial intelligence. Player-adopted strategies in the antiglaucoma drugs market include expanding through strategic acquisitions and collaboration and focusing on development and launch of new drugs.

Recommendations- To take advantage of the opportunities, the business research company recommends the antiglaucoma drugs companies to focus on a new class of medications, focus on research & development, focus on combination medications, provide competitively priced offerings, expand in emerging markets, focus on promoting affordable and effective products efficiently, and leverage e-commerce tools to maximize reach.

Antiglaucoma Drugs Market Segmentation

The antiglaucoma drugs market is segmented by product type, disease condition type, prescription type and by geography.
By Product Type - The antiglaucoma drugs market can be segmented by product type
    • a. Alpha Agonist
    • b. Beta Blockers
    • c. Prostaglandin Analogs
    • d. Combined Medication
    • e. Others
The prostaglandin analogs market was the largest segment of the antiglaucoma drugs market segmented by product type, accounting for 40.8% of the total in 2019. Going forward, the alpha agonist segment is expected to be the fastest growing segment in the antiglaucoma drugs market segmented by product type, at a CAGR of 2.8% during 2019-2023.
By Disease Condition Type –? The antiglaucoma drugs market can be segmented by disease condition type
    • a. Open-Angle Glaucoma
    • b. Angle-Closure Glaucoma
    • c. Normal-Tension Glaucoma
    • d. Congenital Glaucoma
    • e. Other Types Of Glaucoma
The open-angle glaucoma market was the largest segment of the antiglaucoma drugs market segmented by disease condition type, accounting for 64.3% of the total in 2019. Going forward, the angle-closure glaucoma segment is expected to be the fastest growing segment in the antiglaucoma drugs market segmented by disease condition type, at a CAGR of 3.6% during 2019-2023.
By Prescription Type – The antiglaucoma drugs market can be segmented by prescription type
    • a. OTC Drugs
    • b. Prescription Drugs
The prescription drugs market was the largest segment of the antiglaucoma drugs market segmented by prescription type, accounting for 70.9% of the total in 2019. OCT drugs market segment is expected to be the fastest growing segment in the antiglaucoma drugs market segmented by prescription type, at a CAGR of 10.7% during 2019-2023.
By Geography- The antiglaucoma drugs market is segmented into
    • o North America
    • USA
    • o Western Europe
    • France
    • Germany
    • UK
    • o Asia Pacific
    • China
    • Australia
    • India
    • Indonesia
    • Japan
    • South Korea
    • o Eastern Europe
    • Russia
    • o South America
    • Brazil
    • o Middle East
    • o Africa
North America was the largest region in the global antiglaucoma drugs market, accounting for 48.1% of the total in 2019. It was followed by Asia-Pacific and Western Europe, and then the other regions. Going forward, the fastest-growing regions in the antiglaucoma drugs market will be Asia Pacific and South America where growth will be at CAGRs of 5.9% and 2.5% respectively. These will be followed by North America and Africa, where the markets are expected to grow at CAGRs of 1.9% and 1.2% respectively.

Antiglaucoma Drugs Competitive Landscape

Major Competitors are:
    • • Allergen PLC.
    • • Novartis AG
    • • Santen Pharmaceutical Co., Ltd.
    • • Akorn
    • • Pfizer
Other Competitors Include:
    • • Baush Health Companies Inc.
    • • Aerie Pharmaceuticals
    • • Senju Pharmaceuticals
    • • Zydus Cadila
    • • Ocumension Therapeutics
    • • Sun Ophthalmics
    • • Otsuka Pharmaceutical Co., Ltd.
    • • China Resources Zizhu Pharmaceutical Co., Ltd. (CRZP)
    • • Daiichi Sankyo
    • • Alembic Pharmaceuticals
    • • Polfa Warszawa S.A.
    • • Dexcel Pharma
    • • MundiPharma Middle East
    • • Orasis
    • • Bayer
    • • Cipla
    • • Johnson & Johnson
    • • Merck & Co

    Table Of Contents

    1. Antiglaucoma Drugs Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction

    6.1.1. Segmentation By Geography

    6.1.2. Segmentation By Product Type

    6.1.3. Segmentation By Condition Type

    6.1.4. Segmentation By Prescription Type

    7. Antiglaucoma Drugs Market Characteristics

    7.1. Market Definition

    7.2. Market Segmentation By Product Type

    7.2.1. Alpha Agonist

    7.2.2. Beta Blockers

    7.2.3. Prostaglandin Analogs

    7.2.4. Combined Medication

    7.2.5. Others

    7.3. Market Segmentation By Disease Condition Type

    7.3.1. Open-Angle Glaucoma

    7.3.2. Angle-Closure Glaucoma

    7.3.3. Normal-Tension Glaucoma

    7.3.4. Congenital Glaucoma

    7.3.5. Other Types Of Glaucoma

    7.4. Market Segmentation By Prescription Type

    7.4.1. OTC Drugs

    7.4.2. Prescription Drugs

    8. Antiglaucoma Drugs Market Trends And Strategies

    8.1. Rho-Kinase Inhibitors In Glaucoma Treatment

    8.2. Development Of Combination Therapies

    8.3. Investment In Anti-Glaucoma Drugs With Sustained Delivery

    8.4. Investment In Artificial Intelligence For Anti-Glaucoma Drugs

    9. Covid-19 Impact On The Antiglaucoma Drugs Market

    9.1. Introduction

    9.2. Consumer Perception

    9.3. Healthcare Providers Shifting Towards Telehealth Services

    10. Global Antiglaucoma Drugs Market Size And Growth

    10.1. Market Size

    10.2. Historic Market Growth, 2015 – 2019, Value ($ Million)

    10.2.1. Drivers Of The Market 2015 – 2019

    10.2.2. Aging Population

    10.2.3. Restraints Of The Market 2015-2019

    10.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    10.3.1. Drivers Of The Market 2019 – 2023

    10.3.2. Restraints On The Market 2019 – 2023

    11. Global Antiglaucoma Drugs Market Segmentation

    11.1. Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.1.1. Open-Angle Glaucoma

    11.1.2. Angle-Closure Glaucoma

    11.1.3. Normal-Tension Glaucoma

    11.1.4. Other Types Of Glaucoma

    11.1.5. Congenital Glaucoma

    11.2. Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.2.1. Prostaglandin Analogs

    11.2.2. Combined Medication

    11.2.3. Others

    11.2.4. Beta Blockers

    11.2.5. Alpha Agonist

    11.3. Global Antiglaucoma Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.3.1. Prescription Drugs

    11.3.2. OTC Drugs

    12. Antiglaucoma Drugs Market, Regional And Country Analysis

    12.1. Global Antiglaucoma Drugs Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    12.2. Global Antiglaucoma Drugs Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13. Asia-Pacific Antiglaucoma Drugs Market

    13.1. Asia-Pacific Antiglaucoma Drugs Market Overview

    13.1.1. Region Information

    13.1.2. COVID Impact

    13.1.3. Market Information

    13.1.4. Background Information

    13.1.5. Government Initiatives

    13.1.6. Regulations

    13.1.7. Regulatory Bodies

    13.1.8. Major Associations

    13.1.9. Taxes levied

    13.1.10. Corporate Tax Structure

    13.1.11. Investments

    13.1.12. Major Companies

    13.2. Asia-Pacific Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.3. Asia-Pacific Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.4. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.5. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.6. Asia-Pacific Antiglaucoma Drugs Market: Country Analysis

    13.7. China Antiglaucoma Drugs Market

    13.8. China Antiglaucoma Drugs Market Overview

    13.8.1. Country Information

    13.8.2. COVID Impact

    13.8.3. Market Information

    13.8.4. Background Information

    13.8.5. Government Initiatives

    13.8.6. Regulations

    13.8.7. Regulatory Bodies

    13.8.8. Major Associations

    13.8.9. Taxes levied

    13.8.10. Corporate Tax Structure

    13.8.11. Investments

    13.8.12. Major Companies

    13.9. China Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.10. China Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.11. China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.12. China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.13. India Antiglaucoma Drugs Market

    13.14. India Antiglaucoma Drugs Market Overview

    13.14.1. Country Information

    13.14.2. COVID Impact

    13.14.3. Market Information

    13.14.4. Background Information

    13.14.5. Government Initiatives

    13.14.6. Regulations

    13.14.7. Regulatory Bodies

    13.14.8. Major Associations

    13.14.9. Taxes levied

    13.14.10. Corporate Tax Structure

    13.14.11. Investments

    13.14.12. Major Companies

    13.15. India Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.16. India Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.17. India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.18. India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.19. Japan Antiglaucoma Drugs Market

    13.20. Japan Antiglaucoma Drugs Market Overview

    13.20.1. Country Information

    13.20.2. COVID Impact

    13.20.3. Market Information

    13.20.4. Background Information

    13.20.5. Government Initiatives

    13.20.6. Regulations

    13.20.7. Regulatory Bodies

    13.20.8. Major Associations

    13.20.9. Taxes levied

    13.20.10. Corporate Tax Structure

    13.20.11. Investments

    13.20.12. Major Companies

    13.21. Japan Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.22. Japan Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.23. Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.24. Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.25. Australia Antiglaucoma Drugs Market

    13.26. Australia Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.27. Australia Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.28. Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.29. Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.30. Indonesia Antiglaucoma Drugs Market

    13.31. Indonesia Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.32. Indonesia Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.33. Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.34. Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.35. South Korea Antiglaucoma Drugs Market

    13.36. South Korea Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.37. South Korea Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.38. South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.39. South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14. Western Europe Antiglaucoma Drugs Market

    14.1. Western Europe Antiglaucoma Drugs Market Overview

    14.1.1. Region Information

    14.1.2. COVID Impact

    14.1.3. Market Information

    14.1.4. Background Information

    14.1.5. Government Initiatives

    14.1.6. Regulations

    14.1.7. Regulatory Bodies

    14.1.8. Major Associations

    14.1.9. Taxes Levied

    14.1.10. Corporate Tax Structure

    14.1.11. Investments

    14.1.12. Major Companies

    14.2. Western Europe Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.3. Western Europe Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.4. Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.5. Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.6. Western Europe Antiglaucoma Drugs Market: Country Analysis

    14.7. UK Antiglaucoma Drugs Market

    14.8. UK Antiglaucoma Drugs Market Overview

    14.8.1. Region Information

    14.8.2. COVID Impact

    14.8.3. Market Information

    14.8.4. Background Information

    14.8.5. Government Initiatives

    14.8.6. Regulations

    14.8.7. Major Associations

    14.8.8. Taxes Levied

    14.8.9. Corporate Tax Structure

    14.8.10. Investments

    14.8.11. Major Companies

    14.9. UK Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.10. UK Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.11. UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.12. UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.13. Germany Antiglaucoma Drugs Market

    14.14. Germany Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.15. Germany Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.16. Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.17. Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.18. France Antiglaucoma Drugs Market

    14.19. France Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.20. France Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.21. France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.22. France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15. Eastern Europe Antiglaucoma Drugs Market

    15.1. Eastern Europe Antiglaucoma Drugs Market Overview

    15.1.1. Region Information

    15.1.2. COVID Impact

    15.1.3. Market Information

    15.1.4. Background Information

    15.1.5. Government Initiatives

    15.1.6. Regulations

    15.1.7. Regulatory Bodies

    15.1.8. Major Associations

    15.1.9. Taxes Levied

    15.1.10. Corporate Tax Structure

    15.1.11. Investments

    15.1.12. Major Companies

    15.2. Eastern Europe Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    15.3. Eastern Europe Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    15.4. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.5. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.6. Eastern Europe Antiglaucoma Drugs Market: Country Analysis

    15.7. Russia Antiglaucoma Drugs Market

    15.8. Russia Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    15.9. Russia Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    15.10. Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.11. Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16. North America Antiglaucoma Drugs Market

    16.1. North America Antiglaucoma Drugs Market Overview

    16.1.1. Region Information

    16.1.2. COVID-19 Impact

    16.1.3. Market Information

    16.1.4. Background Information

    16.1.5. Government Initiatives

    16.1.6. Regulations

    16.1.7. Regulatory Bodies

    16.1.8. Major Associations

    16.1.9. Tax Levied

    16.1.10. Corporate Tax Structure

    16.1.11. Investments

    16.1.12. Major Companies

    16.2. North America Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    16.3. North America Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    16.4. North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.5. North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.6. North America Antiglaucoma Drugs Market: Country Analysis

    16.7. USA Antiglaucoma Drugs Market Overview

    16.7.1. Country Information

    16.7.2. COVID-19 Impact

    16.7.3. Market Information

    16.7.4. Background Information

    16.7.5. Government Initiatives

    16.7.6. Regulations

    16.7.7. Regulatory Bodies

    16.7.8. Major Associations

    16.7.9. Tax Levied

    16.7.10. Corporate Tax Structure

    16.7.11. Investments

    16.7.12. Major Companies

    16.8. USA Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    16.9. USA Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    16.10. USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.11. USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17. South America Antiglaucoma Drugs Market

    17.1. South America Antiglaucoma Drugs Market Overview

    17.1.1. Region Information

    17.1.2. Impact Of COVID-19

    17.1.3. Market Information

    17.1.4. Background Information

    17.1.5. Government Initiatives

    17.1.6. Regulations

    17.1.7. Regulatory Bodies

    17.1.8. Major Associations

    17.1.9. Tax Levied

    17.1.10. Corporate Tax Structure

    17.1.11. Investments

    17.1.12. Major Companies

    17.2. South America Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    17.3. South America Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    17.4. South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.5. South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.6. South America Antiglaucoma Drugs Market: Country Analysis

    17.7. Brazil Antiglaucoma Drugs Market

    17.8. Brazil Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    17.9. Brazil Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    17.10. Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.11. Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    18. Middle East Antiglaucoma Drugs Market

    18.1. Middle East Antiglaucoma Drugs Market Overview

    18.1.1. Region Information

    18.1.2. COVID Impact

    18.1.3. Market Information

    18.1.4. Background Information

    18.1.5. Government Initiatives

    18.1.6. Regulations

    18.1.7. Regulatory Bodies

    18.1.8. Major Associations

    18.1.9. Taxes Levied

    18.1.10. Corporate Tax Structure

    18.1.11. Investments

    18.1.12. Major Companies

    18.2. Middle East Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    18.3. Middle East Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    18.4. Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    18.5. Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    19. Africa Antiglaucoma Drugs Market

    19.1. Africa Antiglaucoma Drugs Market Overview

    19.1.1. Region Information

    19.1.2. COVID Impact

    19.1.3. Market Information

    19.1.4. Background Information

    19.1.5. Government Initiatives

    19.1.6. Regulations

    19.1.7. Regulatory Bodies

    19.1.8. Major Associations

    19.1.9. Taxes levied

    19.1.10. Corporate Tax Structure

    19.1.11. Investments

    19.1.12. Major Companies

    19.2. Africa Antiglaucoma Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    19.3. Africa Antiglaucoma Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    19.4. Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    19.5. Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    20. Global Antiglaucoma Drugs Market Competitive Landscape

    20.1. Company Profiles

    20.2. Allergen Plc.

    20.2.1. Company Overview

    20.2.2. Products And Services

    20.2.3. Business Strategy

    20.2.4. Financial Overview

    20.3. Novartis AG

    20.3.1. Company Overview

    20.3.2. Products And Services

    20.3.3. Business Strategy

    20.3.4. Financial Overview

    20.4. Santen Pharmaceutical Co., Ltd.

    20.4.1. Company Overview

    20.4.2. Products And Services

    20.4.3. Business Strategy

    20.4.4. Financial overview

    20.5. Akorn

    20.5.1. Company Overview

    20.5.2. Products And Services

    20.5.3. Business Strategy

    20.5.4. Financial Overview

    20.6. Pfizer

    20.6.1. Company Overview

    20.6.2. Products And Services

    20.6.3. Financial Overview

    21. Key Mergers And Acquisitions In The Antiglaucoma Drugs Market

    21.1. Santen Pharmaceutical Acquired Eyevance Holdings LLC

    21.2. Aerie Pharmaceuticals Acquired Avizorex Pharma

    21.3. Santen Pharmaceuticals Co Ltd, Acquired InnFocus Inc.

    21.4. Santen Pharmaceutical Co., Ltd. Acquired Merck’s Ophthalmology Products

    22. Antiglaucoma Drugs Market, Pipeline Analysis

    23. Antiglaucoma Drugs Market Opportunities And Strategies

    23.1. Global Antiglaucoma Drugs Market In 2023 – Countries Offering Most New Opportunities

    23.2. Global Antiglaucoma Drugs Market In 2023 – Segments Offering Most New Opportunities

    23.3. Global Antiglaucoma Drugs Market In 2023 – Growth Strategies

    23.3.1. Market Trend Based Strategies

    23.3.2. Competitor Strategies

    24. Anti-Glaucoma Drugs Market, Conclusions And Recommendations

    24.1. Conclusions

    24.2. Recommendations

    24.2.1. Product

    24.2.2. Price

    24.2.3. Place

    24.2.4. Promotion

    25. Appendix

    25.1. Market Data Sources

    25.2. Research Methodology

    25.3. Currencies

    25.4. Research Inquiries

    25.5. The Business Research Company

    25.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 2: Global Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 3: Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 4: Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 5: Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 6: Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 7: Global Antiglaucoma Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 8: Global Antiglaucoma Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 9: Global Antiglaucoma Drugs Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 10: Global Antiglaucoma Drugs Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 11: Global Antiglaucoma Drugs Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 12: Global Antiglaucoma Drugs Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 13:  Asia Pacific Population By Age Group, 2015-2023, Thousands
  • Table 14: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 15: Asia Pacific GDP Per Capita, 2015-2019, $
  • Table 16: Asia Pacific Glaucoma Prevalence, 2015-2019
  • Table 17: Asia-Pacific Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 18: Asia-Pacific Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 19: Asia-Pacific Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 20: Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 21: Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 22: Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 23: Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 24:  China Population By Age Group, 2015-2023, Thousands
  • Table 25: China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 26: China GDP Per Capita, 2015-2019, $
  • Table 27: China Glaucoma Prevalence, 2015-2019
  • Table 28: China Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 29: China Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • sTable 30: China Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 31: China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 32: China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 33: China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 34: China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 35:  India Population By Age Group, 2015-2023, Thousands
  • Table 36: India Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 37: India GDP Per Capita, 2015-2019, $
  • Table 38: India Glaucoma Prevalence, 2015-2019
  • Table 39: India Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 40: India Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 41: India Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 42: India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 43: India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 44: India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 45: India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 46:  Japan Population By Age Group, 2015-2023, Thousands
  • Table 47: Japan Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 48: Japan GDP Per Capita, 2015-2019, $
  • Table 49: Japan Glaucoma Prevalence, 2015-2019
  • Table 50: Japan Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 51: Japan Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 52: Japan Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 53: Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 54: Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 55: Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 56: Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 57: Australia Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 58: Australia Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 59: Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 60: Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 61: Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 62: Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 63: Indonesia Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 64: Indonesia Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 65: Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 66: Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 67: Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 68: Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 69: South Korea Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 70: South Korea Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 71: South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 72: South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 73: South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 74: South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 75:  Western Europe Population By Age Group, 2015-2023, Thousands
  • Table 76: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 77: Western Europe GDP Per Capita, 2015-2019, $
  • Table 78: Western Europe Glaucoma Prevalence, 2015-2019
  • Table 79: Western Europe Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 80: Taxes Levied On Prescription Drugs In Western European Countries, %
  • Table 81: Western Europe Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 82: Western Europe Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 83: Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 84: Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 85: Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 86: Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 87:  UK Population By Age Group, 2015-2023, Thousands
  • Table 88: UK Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 89: UK GDP Per Capita, 2015-2019, $
  • Table 90: UK Glaucoma Prevalence, 2015-2019
  • Table 91: UK Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 92: UK Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 93: UK Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 94: UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 95: UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 96: UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 97: UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 98: Germany Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 99: Germany Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 100: Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 101: Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 102: Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 103: Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 104: France Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 105: France Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 106: France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 107: France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 108: France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 109: France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 110:  Eastern Europe Population By Age Group, 2015-2023, Thousands
  • Table 111: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 112: Eastern Europe GDP Per Capita, 2015-2019, $
  • Table 113: Eastern Europe Glaucoma Prevalence, 2015-2019
  • Table 114: Eastern Europe Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 115: Eastern Europe Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 116: Eastern Europe Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 117: Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 118: Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 119: Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 120: Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 121: Russia Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 122: Russia Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 123: Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 124: Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 125: Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 126: Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 127:  North America Population By Age Group, 2015-2023, Thousands
  • Table 128: North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 129: North America GDP Per Capita, 2015-2019, $
  • Table 130: North America Glaucoma Prevalence, 2015-2019
  • Table 131: North America Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 132: North America Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 133: North America Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 134: North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 135: North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 136: North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 137: North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 138:  USA Respiratory Masks (N95 Respirators, Surgical Masks, And Others) Market, Population By Age Group, 2015-2023, Thousands
  • Table 139: USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 140: USA GDP Per Capita, 2015-2019, $
  • Table 141: USA Glaucoma Prevalence, 2015-2019
  • Table 142: USA Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 143: USA Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 144: USA Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 145: USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 146: USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 147: USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 148: USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 149:  South America Population By Age Group, 2015-2023, Thousands
  • Table 150: South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 151: South America GDP Per Capita, 2015-2019, $
  • Table 152: South America Glaucoma Prevalence, 2015-2019
  • Table 153: South America Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 154: South America Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 155: South America Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 156: South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 157: South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 158: South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 159: South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 160: Brazil Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 161: Brazil Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 162: Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 163: Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 164: Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 165: Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 166:  Middle East Population By Age Group, 2015-2023, Thousands
  • Table 167: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 168: Middle East GDP Per Capita, 2015-2019, $
  • Table 169: Middle East Glaucoma Prevalence, 2015-2019
  • Table 170: Middle East Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 171: Middle East Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 172: Middle East Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 173: Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 174: Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 175: Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 176: Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 177:  Africa Population By Age Group, 2015-2023, Thousands
  • Table 178: Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 179: Africa GDP Per Capita, 2015-2019, $
  • Table 180: Africa Glaucoma Prevalence, 2015-2019
  • Table 181: Africa Ophthalmic Devices Market Size, 2015-2019, $ Billion
  • Table 182: Africa Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Table 183: Africa Antiglaucoma Drugs Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 184: Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 185: Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 186: Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 187: Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 188: Global Antiglaucoma Drugs Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 189 Allergen Plc. – Financial Performance, 2015 – 2019, $ Billion
  • Table 190: Novartis AG – Financial Performance, 2015 – 2019, $ Billion
  • Table 191: Santen Pharmaceutical Co., Ltd.–  Financial Performance, 2015 – 2019, $ Billion
  • Table 192: Akorn– Financial Performance, 2015-2019, $ Billion
  • Table 193: Pfizer– Financial Performance, 2015 – 2019, $ Billion
  • Table 194: Global Antiglaucoma Drugs Market, Pipeline Analysis
  • Table 195: Global Antiglaucoma Drugs Market Size Gain ($ Million), 2019 – 2023, By Country
  • Table 196: Global Antiglaucoma Drugs Market Size Gain ($ Million), Segmentation By Product type , 2019 – 2023
  • Table 197: Global Antiglaucoma Drugs Market Size Gain ($ Million), Segmentation By Condition Type , 2019 – 2023
  • Table 198: Global Antiglaucoma Drugs Market Size Gain ($ Million), Segmentation By Prescription Type , 2019 – 2023
  • Table 199:  Antiglaucoma Drugs - Market Data Sources

List Of Figures

    Figure 1: Global Antiglaucoma Drugs Market Segmentation By Product Type
  • Figure 2: Global Antiglaucoma Drugs Market Segmentation By Condition Type
  • Figure 3: Global Antiglaucoma Drugs Market Segmentation, By Prescription Type
  • Figure 4: Global Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 5: Global Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 6: Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 7: Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 8: Global Antiglaucoma Drugs Market, Segmentation By Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 9: Global Antiglaucoma Drugs Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 10: Global Antiglaucoma Drugs Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 11: Asia-Pacific Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 12: Asia-Pacific Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 13: Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 14: Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 15: China Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 16: China Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 17: China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 18: China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 19: India Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 20: India Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 21: India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 22: India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 23: Japan Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 24: Japan Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 25: Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 26: Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 27: Australia Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 28: Australia Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 29: Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 30: Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 31: Indonesia Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 32: Indonesia Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 33: Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 34: Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 35: South Korea Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 36: South Korea Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 37: South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 38: South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 39: Western Europe Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 40: Western Europe Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 41: Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 42: Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 43: UK Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 44: UK Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 45: UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 46: UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 47: Germany Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 48: Germany Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 49: Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 50: Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 51: France Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 52: France Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 53: France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 54: France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 55: Eastern Europe Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 56: Eastern Europe Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 57: Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 58: Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 59: Russia Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 60: Russia Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 61: Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 62: Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 63: North America Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 64: North America Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 65: North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 66: North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 67: USA Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 68: USA Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 69: USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 70: USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 71: South America Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 72: South America Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 73: South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 74: South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 75: Brazil Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 76: Brazil Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 77: Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 78: Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 79: Middle East Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 80: Middle East Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 81: Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 82: Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 83: Africa Antiglaucoma Drugs Market, Historic, 2015 – 2019, $ Million
  • Figure 84: Africa Antiglaucoma Drugs Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 85: Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 86: Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 87: Global Antiglaucoma Drugs Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 88: Allergen Plc. – Financial Performance, 2015 – 2019, $ Billion
  • Figure 89: Novartis AG – Financial Performance, 2015 – 2019, $ Billion
  • Figure 90 Santen Pharmaceutical Co., Ltd.– Financial Performance, 2015 – 2019, $ Billion
  • Figure 91: Akorn– Financial Performance, 2015-2019, $ Billion
  • Figure 92: Pfizer– Financial Performance, 2015 – 2019, $ Billion
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the antiglaucoma drugs market?

The antiglaucoma drug market consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and other. The market does not include the sale of biologics used for the treatment of glaucoma. request a sample here

How will the antiglaucoma drugs market drivers and restraints affect antiglaucoma drugs market dynamics? What forces will shape the antiglaucoma drugs industry going forward?

The antiglaucoma drug market growth is aided by government initiatives. However, some antiglaucoma drug market restraints include launch of generic form of the drugs that are priced lower than branded drugs request a sample here

What is the forecast market size of the antiglaucoma drugs market?

The antiglaucoma drug market forecast is expected to reach $8.17 billion in 2025 at a compound annual growth rate of 6%. request a sample here

How is the antiglaucoma drugs market segmented?

The global antiglaucoma drugs market is segmented -
1) By Product Type: Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others
2) By Disease Condition Type: Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma
3) By Type: Hospital Prescription Drugs, Over-the-counter Drugs
request a sample here

Which region has largest share, and what is the market size and growth by geography according to the antiglaucoma drugs global market report?

For more detail on this, request a sample here.

Who are the key players of the global antiglaucoma drugs market?

Top competitors in the antiglaucoma drug market are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare and Johnson & Johnson. request a sample here.

What are the key trends in the global antiglaucoma drugs market?

Major trends influencing the antiglaucoma drug market include developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients request a sample here.

What are the major opportunities in the antiglaucoma drugs market and the approaches companies can take to take advantage of them?

For detail on the future and current opportunities in the global antiglaucoma drugs market, request a sample here.

How does the antiglaucoma drugs market relate to the overall economy and other similar markets?